Selank (10mg) – SL10

Selank (10mg) — Research Peptide

Selank at 10mg per vial provides higher-dose format of this synthetic heptapeptide tuftsin analogue for researchers requiring larger batch volumes or extended experimental timelines. Selank has been registered as a pharmaceutical in Russia (Selank nasal drops) and has undergone controlled clinical trials investigating its anxiolytic, nootropic, and immunomodulatory properties — providing a clinical research foundation uncommon among research peptides.

Published Research Overview

Selank’s most extensively published activities include: anxiolytic effects in rodent models without sedation or dependence liability (open-field, elevated plus maze, Vogel conflict test); modulation of BDNF, NGF, and GDNF expression in hippocampal and cortical tissue; stabilisation of endogenous enkephalin degradation; and immunomodulatory effects on T-cell and NK cell activity in animal models. Russian clinical trials have investigated Selank in generalised anxiety disorder with cognitive outcomes as secondary endpoints.

Product Specifications

• Peptide: Selank (heptapeptide tuftsin analogue)
• Dose: 10mg per vial
• Format: Lyophilised powder, bulk box of 10 vials
• Purity: ≥98% Janoshik HPLC verified
• Storage: -20°C. 24-month stability.

For laboratory research use only. Not for human therapeutic use.